BRWA
ENTA icon

B. Riley Wealth Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

B. Riley Wealth Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-6,462
Closed -$2.45M – 970
2014
Q4 		$2.45M Buy
+6,462
New +$289K 0.05% 488

Other funds holding ENTA

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MVM
McClain Value Management New Canaan, Connecticut $50.9M AUM 16.06% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

B. Riley Wealth Advisors's ENTA Position: Q1 2015 in Review

B. Riley Wealth Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q1 2015, closing a stake of 6,462 shares — an estimated $2.45M sold.

B. Riley Wealth Advisors first reported a position in ENTA in Q4 2014 and held it in 1 quarter. The position peaked at $2.45M in Q4 2014. 118 funds tracked by Wall St. Rank hold ENTA as of Q1 2015.

  • B. Riley Wealth Advisors reported no remaining Enanta Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 6,462 Enanta Pharmaceuticals shares in Q1 2015, an estimated $2.45M.
  • B. Riley Wealth Advisors first reported a position in Enanta Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • B. Riley Wealth Advisors's Enanta Pharmaceuticals position peaked at $2.45M in Q4 2014.
  • 118 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2015.

Based on B. Riley Wealth Advisors's 13F filing for Q1 2015, filed 14 May 2015.